Evidence map›Paper›PMID 22046212›Full record

ArticleOpen medicine : a peer-reviewed, independent, open-access journal2011

Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.

Logan McLeod, Basil G Bereza, Minsup Shim, Paul Grootendorst

Abstract read
In one paragraph

Article in Open medicine : a peer-reviewed, independent, open-access journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.International journal of health policy and management · 2020
    Article
  4. Article
  5. Assessing progressivity and catastrophic effect of out-of-pocket payments for healthcare in Canada: 2010-2015.The European journal of health economics : HEPAC : health economics in prevention and care · 2019
    Article
  6. Article
  7. Review
  8. Article
  9. Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey.The European journal of health economics : HEPAC : health economics in prevention and care · 2017
    Article
  10. The financial burden of out of pocket prescription drug expenses in Canada.International journal of health economics and management · 2015
    Article
  11. Canadian pharmacare: looking back, looking forward.Healthcare policy = Politiques de sante · 2012
    Article
  12. Article
  13. Social benefit payments and acute injury among low-income mothers.Open medicine : a peer-reviewed, independent, open-access journal · 2012
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Logan McLeodSchool of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Basil G Bereza
Minsup Shim
Paul Grootendorst

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommentaries on the adequacy of insurance coverage for prescription drugs available to Canadians have emphasized differences in the coverage provided by different provincial governments. Less is known about the actual financial burden of prescription drug spending and how this burden varies by province of residence, affluence and source of primary drug coverage.

methodsWe used data from a nationally representative household expenditure survey to analyze the financial burden of prescription drugs. We focused on the drug budget share (defined as the share of the household budget spent on prescription drugs), considering how it varied by province, total household budget and likely primary source of drug insurance coverage (i.e., provincial government plan for senior citizens, social assistance plan or private coverage). We examined both "typical" households (at the median of the distribution of the drug budget share) and households with relatively large shares (in the top 5%). Finally, we estimated the percentage of households with catastrophic drug expenditures (defined as a drug budget share of 10% or more) and the average catastrophic drug expenditures.

resultsSenior, social assistance and general population households accounted for 21.1%, 8.9% and 69.9% of the sample of 14,430 respondents to the 2006 Survey of Household Spending, respectively. The median drug budget share in Canada was 1.1% for senior households (range 0.4% [Ontario] to 3.6% [Saskatchewan]) and 0.1% for both social assistance households and general population households, with little appreciable variation across provinces for these latter 2 categories. The 95th percentile drug budget share in Canada was 7.4% for senior households (range 3.5% [Ontario] to 12.7% [Saskatchewan]), 5.4% for social assistance households (range 2.3% [British Columbia] to 13.0% [Prince Edward Island]) and 2.6% for general population households (range 2.1% [Ontario] to 5.4% [Prince Edward Island]). The interprovincial range of the 95th percentile drug budget share was 10.7 percentage points for social assistance households, 9.2 percentage points for senior households and 3.3 percentage points for general population households.

interpretationFor most households, the financial burden of prescription drug expenditures appeared to be relatively small, with little interprovincial variation. However, a small number of households incurred catastrophic drug costs. These households were concentrated in the groups that traditionally benefit from provincial government drug plans. It is likely that some households did not purchase needed prescription drugs because of the expense, so our estimates of the financial burden of catastrophic prescription drug expenditures therefore represent a lower bound.

Indexed as

Cost of IllnessBudgetsConfidence IntervalsCross-Sectional StudiesData CollectionHealth ExpendituresHealth PolicyHealth Services Needs and DemandHumansInsurance CoverageInsurance, Pharmaceutical ServicesOntarioPrescription DrugsPrescription Drugs

Identifiers

PMID22046212
PMCPMC3205811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.